Alpha Thalassemia Market Revenue to Expand Significantly by 2034, States DelveInsight Report | Agios Pharma, Novo Nordisk, Bristol-Myers Squibb, Genmedicn Biopharma

The Key Alpha Thalassemia Companies in the market include - Agios Pharmaceuticals, Novo Nordisk, Bristol-Myers Squibb, Genmedicn Biopharma Ltd., and others.
DelveInsight's "Alpha Thalassemia Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Alpha Thalassemia, historical and forecasted epidemiology as well as the Alpha Thalassemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Alpha Thalassemia, offering comprehensive insights into the Alpha Thalassemia revenue trends, prevalence, and treatment landscape. The report delves into key Alpha Thalassemia statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Alpha Thalassemia therapies. Additionally, we cover the landscape of Alpha Thalassemia clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Alpha Thalassemia treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Alpha Thalassemia space.

To Know in detail about the Alpha Thalassemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Alpha Thalassemia Market Forecast [https://www.delveinsight.com/sample-request/alpha-thalassemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Alpha Thalassemia Market Report:

*
The Alpha Thalassemia market size was valued ~USD 150 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In July 2024, Scientists from the Children's Hospital of Philadelphia (CHOP) and the University of Pennsylvania Perelman School of Medicine have created a groundbreaking model that could pave the way for developing new treatments for Alpha Thalassemia (AT), a severe blood disorder. Their research, published in the journal Blood, highlights the global impact of AT, with thousands of children affected each year, particularly in regions like Southeast Asia, India, the Middle East, and the Mediterranean. While the genetic trait offers protection against malaria and typically results in mild anemia, children born to parents who both carry defective genes are at a much higher risk of developing severe forms of AT.

*
In January 2024, Agios Pharmaceuticals announced promising results from the Phase III ENERGIZE trial evaluating mitapivat for non-transfusion-dependent alpha- or beta-thalassemia, achieving both the primary endpoint and two key secondary endpoints. The company plans to pursue regulatory approval for mitapivat as a treatment for thalassemia by the end of the year, leveraging data from the second Phase III ENERGIZE-T study (NCT04770779), which focuses on adults with transfusion-dependent alpha- or beta-thalassemia.

*
The Alpha Thalassemia market size in the US was estimated at over USD 70 million in 2023 and is projected to grow throughout the forecast period (2024-2034).

*
Within the EU4 and the UK, Italy held the largest share of the Alpha Thalassemia market, with a market size of USD 30 million in 2023, anticipated to expand during the forecast period (2024-2034).

*
Key Alpha Thalassemia Companies: Agios Pharmaceuticals, Novo Nordisk, Bristol-Myers Squibb, Genmedicn Biopharma Ltd., and others

*
Key Alpha Thalassemia Therapies: Mitapivat, Etavopivat, Luspatercept, GMCN-508A, and others

*
The Alpha Thalassemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Alpha Thalassemia pipeline products will significantly revolutionize the Alpha Thalassemia market dynamics.

*
In 2023, the United States had the highest prevalence of alpha thalassemia among the 7MM, with over 1,400 cases. This number is projected to grow over the forecast period.

*
In 2023, among the EU4 and the UK, Italy reported the highest number of prevalent alpha thalassemia cases, while France had the fewest.

*
Our analysis indicates that cases of non-transfusion-dependent thalassemia (NTDT) exceeded those of transfusion-dependent thalassemia (TDT).

Alpha Thalassemia Overview

Alpha thalassemia is a genetic blood disorder caused by mutations in the genes responsible for producing alpha-globin, a component of hemoglobin. Hemoglobin is essential for carrying oxygen throughout the body, and a deficiency in alpha-globin leads to abnormal red blood cells and reduced oxygen transport. The condition ranges in severity, from silent carriers with no symptoms to severe forms like Hemoglobin H disease and alpha thalassemia major, which can cause life-threatening anemia. Common symptoms include fatigue, pale skin, and growth delays. Treatment depends on severity and may include blood transfusions, iron chelation therapy, or bone marrow transplantation.

Get a Free sample for the Alpha Thalassemia Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/alpha-thalassemia-market [https://www.delveinsight.com/report-store/alpha-thalassemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Alpha Thalassemia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Alpha Thalassemia Epidemiology Segmentation:

The Alpha Thalassemia market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Alpha Thalassemia

*
Prevalent Cases of Alpha Thalassemia by severity

*
Gender-specific Prevalence of Alpha Thalassemia

*
Diagnosed Cases of Episodic and Chronic Alpha Thalassemia

Download the report to understand which factors are driving Alpha Thalassemia epidemiology trends @ Alpha Thalassemia Epidemiology Forecast [https://www.delveinsight.com/sample-request/alpha-thalassemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Alpha Thalassemia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Alpha Thalassemia market or expected to get launched during the study period. The analysis covers Alpha Thalassemia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Alpha Thalassemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Alpha Thalassemia Therapies and Key Companies

*
Mitapivat: Agios Pharmaceuticals

*
Etavopivat: Novo Nordisk

*
Luspatercept: Bristol-Myers Squibb

*
GMCN-508A: Genmedicn Biopharma Ltd.

Alpha Thalassemia Market Drivers

*
Increasing Prevalence genetic disorders and advancement in healthcare technologies, growing demand for treatment for Alpha Thalassemia are some of the important factors that are fueling the Alpha Thalassemia Market.

Alpha Thalassemia Market Barriers

*
However, lack of available appropriate treatments and procedures, high cost of treatment and other factors are creating obstacles in the Alpha Thalassemia Market growth.

Scope of the Alpha Thalassemia Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Alpha Thalassemia Companies: Agios Pharmaceuticals, Novo Nordisk, Bristol-Myers Squibb, Genmedicn Biopharma Ltd., and others

*
Key Alpha Thalassemia Therapies: Mitapivat, Etavopivat, Luspatercept, GMCN-508A, and others

*
Alpha Thalassemia Therapeutic Assessment: Alpha Thalassemia current marketed and Alpha Thalassemia emerging therapies

*
Alpha Thalassemia Market Dynamics: Alpha Thalassemia market drivers and Alpha Thalassemia market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Alpha Thalassemia Unmet Needs, KOL's views, Analyst's views, Alpha Thalassemia Market Access and Reimbursement

To know more about Alpha Thalassemia companies working in the treatment market, visit @ Alpha Thalassemia Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/alpha-thalassemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Alpha Thalassemia Market Report Introduction

2. Executive Summary for Alpha Thalassemia

3. SWOT analysis of Alpha Thalassemia

4. Alpha Thalassemia Patient Share (%) Overview at a Glance

5. Alpha Thalassemia Market Overview at a Glance

6. Alpha Thalassemia Disease Background and Overview

7. Alpha Thalassemia Epidemiology and Patient Population

8. Country-Specific Patient Population of Alpha Thalassemia

9. Alpha Thalassemia Current Treatment and Medical Practices

10. Alpha Thalassemia Unmet Needs

11. Alpha Thalassemia Emerging Therapies

12. Alpha Thalassemia Market Outlook

13. Country-Wise Alpha Thalassemia Market Analysis (2020-2034)

14. Alpha Thalassemia Market Access and Reimbursement of Therapies

15. Alpha Thalassemia Market Drivers

16. Alpha Thalassemia Market Barriers

17. Alpha Thalassemia Appendix

18. Alpha Thalassemia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=alpha-thalassemia-market-revenue-to-expand-significantly-by-2034-states-delveinsight-report-agios-pharma-novo-nordisk-bristolmyers-squibb-genmedicn-biopharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.